Navigation Links
New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
Date:12/9/2010

al regions.

LUX-Lung 4 is a phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment.  

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.

About Lung Cancer

Lung cancer is the second most common cancer and kills more people than any other cancer.  In 2010, approximately 222,250 new cases of lung cancer will be diagnosed in the United States, with 157,300 Americans dying from the disease. NSCLC is the most common form of lung cancer, accounting for about 85 percent of all lung cancers.(3)  Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. There is no FDA-approved therapy for patients with advanced lung cancer who have failed chemotherapy and progressed after treatment with an EGFR-TKI.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogene
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)... Sept. 18, 2014  LABSCO, the leading ... and products to hospitals, physician office laboratories ... amended distributorship agreement with Sysmex America.  This ... instruments, including the Sysmex XS-1000 i ™, ... and XN-Series Automated Hematology Analyzers. ...
(Date:9/18/2014)... -- According to the new research ... Warming & Cooling), Application (Acute & Perioperative Care, ... & Paramedical Staff) - Global Forecasts & Trends ... global Temperature Management Market over the forecast period ... to reach $2.5 Billion by 2019 at CAGR ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4
... EyeScience(TM) ( www.eyescience.com ) announced today that ... and Dry Eye Formula(TM) are the only ... from their offices and through mass market retail. This announcement ... growing demand for the most complete eye vitamins available for ...
... (Nasdaq: HOLX ) today announced that Jack Cumming, Chairman, ... London on Tuesday, December 1, 2009, at 11:15am (GMT). ... audio webcast of Hologic,s investor presentation on the investor section ... An archive of the presentation will be available for replay ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3
(Date:9/19/2014)... Business Insider Australia Rates Appy Pie as a ... Appy Pie was also listed as one of the ... Yahoo . , Appy Pie a leading cloud based DIY ... minutes and it requires no coding knowledge or previous experience ... mobile operating systems, the apps created using their platform are ...
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 The ... a special promotion for new patients. Throughout the month of ... dental exam with dental X-rays for just $69. A complimentary ... patients to get their teeth and gums checked and meet ... are among the best ways to protect oral health. According ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. 18, ... got a flu shot last year, so U.S. health officials ... vaccinated for the coming flu season. "It,s really unfortunate ... flu they could get," said Dr. Thomas Frieden, director of ... morning news conference. The result is lost days from ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
(Date:9/19/2014)... LENEXA, Kan. (PRWEB) September 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for St. John’s Episcopal Hospital in Far Rockaway, N.Y. ... B. E. Smith has recently placed more than 900 ... Hospital is a faith-based, full service community hospital serving ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... to the brain can be devastating. When brain cells die, ... glutamate floods the surrounding areas, overloading the cells in its ... swathes of tissue. ,Glutamate is always present ... gaps between cells. But when this chemical is released by ...
... infections in parts of Cambodia is being extended to an ... 40,000 residents, an expert said. ,Although malaria-infected mosquitoes ... the real source of the disease is people, some of ... time without showing clear symptoms. ,Moheli island, the ...
... responsible for staphylococcus infections can kill infected patients in ... by the name of PVL or otherwise called Panton ... and harm the healthy tissue as well. ... infections. This is normally found in the skin or ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... Center researchers have identified an approach to enhance the ... shown impressive efficacy in the treatment of chronic myelogenous ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate (Gleevec) is a ...
... is probing the link between breast density and its implication ... novel study on 1,112 women has brought to the fore, ... with dense breasts. The study revealed that, those with dense ... breast cancer, compared to women with fatty tissue in the ...
Cached Medicine News:Health News:New Method May Treat Brain Injuries 2Health News:Chinese Scientists Take Malaria Fight to Africa 2Health News:New Strategy for the Treatment of CML 2Health News:New Strategy for the Treatment of CML 3
Duckbill type, sharp. 3 mm x 8 mm curved blade. Octagonal handle....
10 mm wide tip....
9 mm wide tip. 35 mm from angle to tip....
Designated most popular model or size. 4 mm wide tip....
Medicine Products: